Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies
P Lampertico, D Roulot, H Wedemeyer - Journal of hepatology, 2022 - Elsevier
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, characterised by the
greatest increase in risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma.
Pegylated-interferon-α (pegIFNα), the only off-label therapeutic option, has been available
for the last 30 years but is associated with suboptimal response rates and poor tolerability.
Among the new treatment strategies under clinical evaluation, the entry inhibitor bulevirtide
(BLV) is the only one that has received conditional approval from the European Medicines …
greatest increase in risk of cirrhosis, hepatic decompensation and hepatocellular carcinoma.
Pegylated-interferon-α (pegIFNα), the only off-label therapeutic option, has been available
for the last 30 years but is associated with suboptimal response rates and poor tolerability.
Among the new treatment strategies under clinical evaluation, the entry inhibitor bulevirtide
(BLV) is the only one that has received conditional approval from the European Medicines …
